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Michael Rieder MD PhD FRCPC, Gideon Koren MD FRCPC

A

LEARNING POINTS
• Codeine is a prodrug and, by itself, has relatively poor
analgesic effects (1). These effects are due to the metabolism

of codeine to morphine by CYP2D6, which is further
metabolized by glucuronidation to morphine 3-glucuronide
(an inactive metabolite) and morphine 6-glucuronide (an
active metabolite).
• Codeine and morphine undergo polymorphic metabolism
(1-3), with genetically determined variability.
Codeine metabolism has three well-recognized phenotypes with respect to CYP2D6:
Poor metabolizers: reduced enzyme activity with likely
less morphine production;
Extensive metabolizers: the most common phenotype
(90% in northern European populations) with efficacy
and toxicity of codeine best established; and
Ultrarapid metabolizers: increased enzyme activity with
likely markedly more morphine production (1,2).
Polymorphisms in CYP2D6 are not uniformly distributed
across the world (1,2). In northern Europe, ultrarapid metabolizers make up 1% of the population, the Mediterranean 8%,
and the Horn of Africa, the Middle East and South India
20% to 25%.
Polymorphisms of morphine glucuronidation have been
described, favouring the production of the active metabolite
versus the inactive one, which would tend to exaggerate the
effects of a dose of morphine or codeine (4).
• The combination of key polymorphisms can create a
‘perfect storm’, in which newborns can be presented with
excessive doses of morphine in the context of endogenous
metabolism that favours production of an active metabolite
(5,6).
• The clinical effects of opiates are not arcane (7). A careful
history and physical examination, and keeping an open
mind to diagnostic possibilities remain essential. This baby
had the classical combination of lethargy and bradypnea
associated with opiate overdose. Significantly, the mother
also had complaints suggestive of opiate overdose including
lethargy and constipation. It would have been easy to
consider sepsis alone as a diagnosis, but had this occurred
and the baby continued to be breastfed, unfortunate (and
even fatal) consequences might have ensued.
• Potent drugs have potent adverse events. When
prescribing opiates for women in the postpartum period
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one-week-old boy was seen in the emergency department with a two-day history of poor feeding and
increasing lethargy. He was born at term after an uneventful
pregnancy by repeat caesarean section. His birth weight
was 3.2 kg. The patient’s Apgar scores were 8 and 9, and he
was discharged home on day 3 with exclusive breastfeeding.
He has two older siblings: a five-year-old sister born in the
mother’s homeland of Sri Lanka, and a three-year-old
brother born in Canada by caesarean section because of
failure to progress. Both siblings and the parents are in good
health, and there was no significant family history.
On examination, the baby was a term male infant, afebrile
with a blood pressure of 75/45 mmHg, heart rate of 120 beats/
min and shallow respirations with a rate of 16 breaths/min.
He did not respond well to stimuli and had a poor suck. His
physical examination was otherwise unremarkable.
A full septic workup was performed, with unremarkable
results. During the process of the workup, a urine drug screen
was sent, which was positive for opiates. More specific analysis revealed a serum morphine concentration of 55 µg/mL – a
potentially toxic concentration. A 0.01 mg/kg dose of naloxone was administered, with good clinical improvement.
Further questioning revealed that the mother was given
an acetaminophen-codeine product for analgesia postcaesarean section. She had been having increasing pain after
discharge because she was caring for her newborn plus two
busy older siblings. She reported taking one or two pain
tablets three or four times a day, and noted excellent pain
relief but also drowsiness and constipation.
Genetic testing was performed to investigate the maternal
and infant pathways of codeine and morphine metabolism.
The mother was shown to have a gene duplication for cytochrome P450 2D6 (CYP2D6), which classified her as an
ultrarapid metabolizer. The mother was also found to be
homozygous for the UGT 2B7*2 allele, a polymorphism in
the glucuronidation of morphine associated with increased
production of morphine 6-glucuronide, the active metabolite
of morphine. This ‘two-hit’ genetic variation would expose
her newborn to very high concentrations of morphine and
the active metabolite of morphine via breast milk.
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or while breastfeeding, it is key to advise on symptoms to
watch for, in themselves and in their infants, and when
to seek medical advice (7). Careful follow-up needs to be
assurred. Of note, the use of alternative opiates, such as
oxycodone, does not prevent these problems because
many opiates are metabolized by common pathways.
One should also use codeine with care for other
indications in children, such as for postoperative pain
(8).
• If possible, during breastfeeding, codeine should not be
used for longer than four days. If pain still persists, an
attempt should be made to decrease the dose of codeine or
switch to a nonsteroidal anti-inflammatory drug (9).
• The present case points to the future of drug prescribing.
There are now assays to determine the genotype of the
key pathways involved in codeine bioactivation, and
studies are currently being conducted to determine the
role of such testing in the personalized therapy of women
postpartum. Clinicians are well advised to watch for the
results of these studies.

